TRVI Trevi Therapeutics, Inc.

NASDAQ
$14.41

Trevi Therapeutics, Inc. (TRVI) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.13 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -25.2% since its last earnings release on August 6, 2026.

Trevi Therapeutics Reported In-line with Estimates
Thursday, August 6, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.13)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $16.76

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.